Graphite Bio hands Nas­daq spot to pres­by­opia biotech Lenz Ther­a­peu­tics as PhI­II read­outs loom

Nine months af­ter throw­ing in the tow­el on its gene edit­ing pro­gram for sick­le cell dis­ease, Graphite Bio said it has found a re­verse merg­er part­ner to take its spot on the Nas­daq.

Pres­by­opia drug de­vel­op­er Lenz Ther­a­peu­tics will take Graphite’s place and will have enough fund­ing to take it all the way to com­mer­cial­iza­tion, should its lead eye drop can­di­date get FDA ap­proval, the com­pa­nies said Wednes­day morn­ing. They ex­pect the deal to close in the first quar­ter of next year, at which point Lenz would start its pub­lic life as $LENZ.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER